2M7C.F China Medical System Holdings Limited
- Market cap
- EUR 2.85B
- P/E
- 14.6x
- P/B
- 1.19x
- ROE
- 8.6%
- Dividend yield
- 3.21%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 2M7C.F undervalued?
Graham number2M7C.F trades 12.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
China Medical System Holdings Limited fundamental analysis
No fundamental analysis for China Medical System Holdings Limited yet.
China Medical System Holdings Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About China Medical System Holdings Limited
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; …
Full company profileChina Medical System Holdings Limited financial statements
China Medical System Holdings Limited annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 4.90B | 5.35B | 5.43B | 6.07B | 6.95B | 8.34B | 9.15B | 8.01B | 7.47B | 8.21B |
| Gross Profit | 2.91B | 3.48B | 3.92B | 4.55B | 5.13B | 6.25B | 7.04B | 6.11B | 5.42B | 5.87B |
| Operating Income | 1.55B | 1.90B | 2.01B | 2.40B | 2.81B | 3.22B | 3.65B | 2.83B | 1.73B | 1.64B |
| EBITDA | - | 2.09B | 2.28B | 2.75B | 2.84B | 3.48B | 4.04B | 3.15B | 2.31B | 2.39B |
| Net Income | 1.38B | 1.67B | 1.85B | 1.96B | 2.53B | 3.02B | 3.26B | 2.40B | 1.62B | 1.49B |
| EPS | - | 0.67 | 0.75 | 0.79 | 1.02 | 1.23 | 1.33 | 0.98 | 0.66 | 0.61 |
| Balance Sheet | ||||||||||
| Total Assets | 9.79B | 10.1B | 10.5B | 11.2B | 12.7B | 15.8B | 17.8B | 17.7B | 18.0B | 19.2B |
| Total Liabilities | 3.52B | 2.82B | 2.10B | 1.65B | 1.60B | 2.96B | 3.02B | 2.17B | 1.64B | 1.66B |
| Shareholders' Equity | 6.21B | 7.27B | 8.36B | 9.47B | 11.0B | 12.8B | 14.6B | 15.5B | 16.3B | 17.4B |
| Cash & Short-term Investments | 482M | 856M | 815M | 1.37B | 2.67B | 3.39B | 4.38B | 4.31B | 3.71B | 2.70B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 1.16B | 2.07B | 1.75B | 2.56B | 2.69B | 2.49B | 3.55B | 2.50B | 1.27B | 758M |
| Capital Expenditure | 1.07B | 76.6M | 33.9M | 37.5M | 37.6M | 23.3M | 18.3M | 318M | 456M | 514M |
| Free Cash Flow | - | 2.00B | 1.69B | 2.21B | 2.69B | 2.49B | 3.03B | 2.18B | 813M | 244M |
| Ratios | ||||||||||
| ROE | 22.2% | 23.0% | 22.1% | 20.7% | 22.9% | 23.7% | 22.3% | 15.5% | 9.9% | 8.6% |
| ROA | 14.1% | 16.5% | 17.6% | 17.6% | 19.9% | 19.1% | 18.4% | 13.5% | 9.0% | 7.8% |
| Net Profit Margin | 28.1% | 31.3% | 34.0% | 32.3% | 36.4% | 36.2% | 35.6% | 30.0% | 21.7% | 18.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
China Medical System Holdings Limited dividends
- Dividend yield
- 3.21%
- Forward dividend
- 0.04 EUR
- Payout ratio
- 44.4%
- Ex-dividend date
- Aug 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 661M | 0.27 | 44.4% |
| 2024 | CNY 556M | 0.23 | 34.3% |
| 2023 | CNY 1.36B | 0.55 | 56.7% |
| 2022 | CNY 1.28B | 0.52 | 39.2% |
| 2021 | CNY 1.15B | 0.47 | 38.3% |
| 2020 | CNY 834M | 0.34 | 33.0% |
| 2019 | EUR 823M | 0.33 | 42.0% |
| 2018 | EUR 729M | 0.29 | 39.4% |
| 2017 | EUR 611M | 0.25 | 36.5% |
| 2016 | EUR 463M | - | 33.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:2 on Apr 27, 2012.
Who owns China Medical System Holdings Limited
- Insiders 48.28%
- Institutions 25.31%
- Public & others 26.41%
- Shares outstanding 2.43B
- Free float 1.26B
China Medical System Holdings Limited company profile
- Company name
- China Medical System Holdings Limited
- Ticker
- 2M7C.F
- ISIN
- KYG211081248
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 6,415
- Fiscal year end
- December
- Address
- Island Place Tower, North Point, Hong Kong
- Phone
- 852 2369 7678
- Website
- web.cms.net.cn
About China Medical System Holdings Limited
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate depression. It also provides gastroenterology products, such as METOJECT, a methotrexate injection to treat severe recalcitrant disabling psoriasis and rheumatoid arthritis; LUMEBLUE, a methylthioninium chloride enteric-coated sustained-release tablets for colorectal lesion visualization; Salofalk for ulcerative colitis and Crohn's disease; Bioflor, a saccharomyces boulardii sachets for diarrhea; Combizym and Cidine for digestive enzymes; and Ursofalk, a ursodeoxycholic acid capsules to treat cholesterol gallstones. In addition, the company offers dermatology products, including ILUMETRI, a tildrakizumab injection for the treatment of plaque psoriasis; Aethoxysklerol, a polidocanol injection for sclerotherapy of various varicose veins; Hirudoid, a mucopolysaccharide polysulfate cream to treat blunt traumata; skin heling soothing product; and Hirudoid for acne-prone skin care, prevention, and enhancement of acne. Further, it provides Vmonalisa, modified sodium hyaluronate filler for mid to deep dermal implantation; augentropfen stulln mono eye drops for asthenopia; EyeOP1 glaucoma treatment device; and Elcitonin for Osteoporosis pain. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
China Medical System Holdings Limited management
9- Dr. Kong LamFounder, Chairman, CEO & President · born 1965
- Ms. Yanling ChenCFO, VP & Executive Director · born 1970
- Mr. Lieyi MaGeneral Manager of the Operations & Management Center of the Group · born 1970
- Liu YueDirector of Investor Relations
- Ms. Sanyan WuDirector of Legal Department & Company Secretary · born 1983
- Dr. Huaizheng Peng M.D., Ph.D.Chief Business Officer · born 1962
- Mr. Fei JiangChief Investment Officer of Greater China · born 1977
- Mr. James Patrick StearnsChief Investment Officer of Europe & America · born 1979
- Mr. Anjun HuangGeneral Manager of Skin Health Business of DERMAVON